Mercury Biopharmaceutical Company Description

Mercury Biopharmaceutical Corporation engages in the development of drugs for unmet needs in Taiwan.

The company develops StackDose platform, a drug development platform to produce new dosage forms with precise time-controlled dissolution, precise site absorption, and various dosage adjustments to enhance the bio-availability of active pharmaceutical ingredients to reduce the dosage of drugs and its side effects.

It develops drugs for treating erectile dysfunction, pulmonary hypertension, sleep disorder, benign prostatic hyperplasia, angina pectoris, migraine, anti-hypertension, and analgesic.

The company was founded in 2019 and is based in New Taipei City, Taiwan.

Mercury Biopharmaceutical Corporation

Country	Taiwan
Founded	2019
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
CEO	Yaoren Liang

Contact Details

Address: 15th Floor New Taipei City Taiwan
Phone	886 2 8221 2020
Website	merdury.com

Stock Details

Ticker Symbol	6932
Exchange	Taipei Exchange
Fiscal Year	January - December
Reporting Currency	TWD
ISIN Number	TW0006932007
SIC Code	2834

Key Executives

Name	Position
Yaoren Liang	GM and Director
Chun Chun Zhang	Accounting Supervisor